When does Anterix's share-repurchase authorization expire?

The authorization expires on September 21, 2026. Since the filing is dated August 11, 2026, the company has approximately 41 days remaining to complete repurchases under this program before it terminates unless renewed by the board.

Why did Anterix conduct no share repurchases in Q1 FY2027?

The filing does not explicitly state the reason for zero repurchase activity during the quarter. The company may have prioritized other capital allocation decisions or chosen to preserve liquidity for operational and strategic investments in spectrum clearing.

How much of the authorization has been used so far?

Approximately $23.3 million has been repurchased under the $250 million program, leaving $226.7 million available as of June 30, 2026. This means roughly 91% of the authorization remains unused.

Does Anterix have sufficient liquidity to complete remaining repurchases?

Yes. The company reported $116.0 million in cash and cash equivalents with no debt as of June 30, 2026, providing ample capacity to execute the remaining $226.7 million authorization if elected before the September 21, 2026 deadline.

What is the execution mechanism for the buyback program?

The filing does not specify whether repurchases will be executed through open-market purchases under Rule 10b-18, accelerated share repurchase (ASR) agreements, or another method. This detail is not disclosed in the press release.

How many shares does Anterix currently have outstanding?

As of June 30, 2026, Anterix had 19,550,348 shares issued and outstanding, an increase from 18,914,271 shares at March 31, 2026, driven by stock option exercises totaling $20.3 million in proceeds during the quarter.

ATEX 8-K Filed 2026-08-11 New authorization

Anterix maintains $250M share-repurchase program through Sept. 2026

Company had no repurchase activity in Q1 FY2027; $226.7M remains available under existing authorization.

Authorization$250M

Remaining$227M

MechanismNot specified

What the filing says

Anterix Inc. reported in its Q1 FY2027 earnings release that the Company has an authorized share repurchase program for up to $250.0 million of common stock on or before September 21, 2026. During the first quarter of fiscal 2027 ended June 30, 2026, Anterix had no share repurchase activity. As of the quarter-end date, $226.7 million remained available for repurchase under the program, indicating that $23.3 million has been deployed under the authorization to date.

The authorization remains active with an expiration date of September 21, 2026. At quarter-end, the Company maintained a strong liquidity position with cash and cash equivalents of $116.0 million and no debt, providing ample capacity to execute repurchases if elected. The Company's decision to conduct no repurchases in Q1 reflects operational and capital allocation priorities focused on spectrum clearing costs and customer payment timing.

The Company has an authorized share repurchase program for up to $250.0 million of the Company's common stock on or before September 21, 2026. In fiscal 2027 first quarter, Anterix had no share repurchase activity. As of June 30, 2026, $226.7 million remained available under the share repurchase program. — Anterix Inc. 8-K filing · View on SEC EDGAR →

What this means

Anterix disclosed an active $250 million share-repurchase authorization with an expiration of September 21, 2026, leaving roughly $226.7 million available. The company executed no repurchases during Q1 FY2027, choosing instead to deploy capital toward spectrum clearing and customer-facing initiatives. With a debt-free balance sheet and $116 million in cash, the company retains substantial flexibility to repurchase shares before the program expires, though the near-term deadline limits the window for execution.

Frequently asked questions

When does Anterix's share-repurchase authorization expire?: The authorization expires on September 21, 2026. Since the filing is dated August 11, 2026, the company has approximately 41 days remaining to complete repurchases under this program before it terminates unless renewed by the board.
Why did Anterix conduct no share repurchases in Q1 FY2027?: The filing does not explicitly state the reason for zero repurchase activity during the quarter. The company may have prioritized other capital allocation decisions or chosen to preserve liquidity for operational and strategic investments in spectrum clearing.
How much of the authorization has been used so far?: Approximately $23.3 million has been repurchased under the $250 million program, leaving $226.7 million available as of June 30, 2026. This means roughly 91% of the authorization remains unused.
Does Anterix have sufficient liquidity to complete remaining repurchases?: Yes. The company reported $116.0 million in cash and cash equivalents with no debt as of June 30, 2026, providing ample capacity to execute the remaining $226.7 million authorization if elected before the September 21, 2026 deadline.
What is the execution mechanism for the buyback program?: The filing does not specify whether repurchases will be executed through open-market purchases under Rule 10b-18, accelerated share repurchase (ASR) agreements, or another method. This detail is not disclosed in the press release.
How many shares does Anterix currently have outstanding?: As of June 30, 2026, Anterix had 19,550,348 shares issued and outstanding, an increase from 18,914,271 shares at March 31, 2026, driven by stock option exercises totaling $20.3 million in proceeds during the quarter.

authorization share-repurchase-program spectrum-sector no-repurchase-activity debt-free

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.